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GObjectives: We investigated the feasibility and safety of four-arm robotic lung lobectomy in patients with lung
cancer and described the robotic lobectomy technique with mediastinal lymph node dissection.
Methods: Over 21 months, 54 patients underwent robotic lobectomy for early-stage lung cancer at our institute.
We used a da Vinci Robotic System (Intuitive Surgical, Inc, Mountain View, Calif) with three ports plus one util-
ity incision to isolate hilum elements and perform vascular and bronchial resection using standard endoscopic
staplers. Standard mediastinal lymph node dissection was performed subsequently. Surgical outcomes were com-
pared with those in 54 patients who underwent open surgery over the same period and were matched to the robotic
group using propensity scores for a series of preoperative variables.
Results: Conversion to open surgery was necessary in 7 (13%) cases. Postoperative complications (11/54, 20%,
in each group) and median number of lymph nodes removed (17.5 robotic vs 17 open) were similar in the 2
groups. Median robotic operating time decreased by 43 minutes (P ¼ .02) from first tertile (18 patients) to the
second-plus-third tertile (36 patients). Median postoperative hospitalization was significantly shorter after robotic
(excluding first tertile) than after open operations (4.5 days vs 6 days; P ¼ .002).
Conclusions: Robotic lobectomy with lymph node dissection is practicable, safe, and associated with shorter
postoperative hospitalization than open surgery. From the number of lymph nodes removed it also appears onco-
logically acceptable for early lung cancer. Benefits in terms of postoperative pain, respiratory function, and qual-
ity of life still require evaluation. We expect that technologic developments will further simplify the robotic
procedure. (J Thorac Cardiovasc Surg 2010;140:19-25)Lung cancer screening programs in at-risk populations are
resulting in increased numbers of early-stage lung cancers
potentially best removed by minimally invasive surgical
approaches.1,2 Thoracoscopic lobectomy has been shown to
be safe and effective, with benefits in terms of reduced postop-
erative pain and better functional and aesthetic results com-
pared with open lobectomy.3-10 Observational studies5-7 and
at least one randomized trial3 indicate that oncologic results
are equivalent to those of open surgery.However, thoracic sur-
geons seem reluctant to embrace video-assisted thoracic sur-
gery (VATS) owing to the limited maneuverability and
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The Journal of Thoracic and Cthe limitations of the 2-dimensional viewof the operatingfield,
and persisting controversy regarding oncologic efficacy.11,12
The da Vinci Robotic System (Intuitive Surgical, Inc,
Mountain View, Calif) for thoracoscopic surgery overcomes
many of the disadvantages of traditional VATS in that it has
a superior range of motion and improved ergonomic charac-
teristics, as well as offering 3-dimensional visibility. In addi-
tion, surgeons appear to adapt quicker to the surgical robot,
and the technology may provide a greater probability of on-
cologic radicality. At present, very few centers use the da
Vinci System to treat lung cancer. Nevertheless, published
early experience is encouraging, although the series were
small and not compared with open procedures.13-15
The aims of the present study are to evaluate the feasibility
and safety of the da Vinci System when used to perform pul-
monary lobectomy for early-stage lung cancer and to pro-
vide indications as to oncologic efficacy by assessing the
number of mediastinal lymph nodes removed in comparison
with a matched group of patients subjected to open lobec-
tomy for lung cancer. A further aim is to describe our
four-arm robotic technique for lobectomy and lymph node
removal.
METHODS
From November 2006 through September 2008, 54 patients with sus-
pected or proven clinical stage I or II lung cancer were recruited to undergoardiovascular Surgery c Volume 140, Number 1 19
Abbreviations and Acronyms
CT ¼ computed tomography
FEV1 ¼ forced expiratory volume in 1 second
VATS ¼ video-assisted thoracic surgery
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lesion less than 5 cm, normal respiratory function (including forced expira-
tory volume in 1 second [FEV1] greater than 65% of predicted), no prior
thoracic surgery, no neoadjuvant treatment, no need for extended or sleeve
resection, and age less than 75 years. All patients underwent complete pre-
operative staging including positron emission tomography, bronchoscopy
with brushing or biopsy, and whole-body computed tomography (CT)
(2.5-mm slices). Mediastinoscopy was performed in cases in which visual
assessment of positron emission tomographic scans suggested mediastinal
adenopathy. Over the study period, 132 other patients underwent conven-
tional lobectomy and 54 a sublobar resection. Only candidates for lobec-
tomy (never those for wedge resection) were potential candidates for
robotic lobectomy. We compared the 54 patients having robotic lobectomy
with 54 patients having open lobectomy, selected using propensity scores
(see Statistical Analysis).
Operating time, postoperative hospitalization, perioperative and postop-
erative complications, and number of mediastinal lymph nodes removed
were recorded prospectively in the robotic group and in a group of 54 pa-
tients who received open lobectomies at our center over same period. CT-
guided biopsy was not performed on a routine basis.
All robotic lobectomies were performed by one surgeon (G.V.) experi-
enced in major lung resection but with no direct experience of VATS lobec-
tomy. The open procedures (lateral muscle-sparing approach) were
performed by one of the four senior surgeons (including G.V.) at the Thoracic
Surgery Division, Milan. Patients were chosen for the robotic as opposed to
the open approach in a nonrandom fashion determined by surgeon choice,
da Vinci System availability, (limited to 3 to 4 cases per month over the study
period), and position of lung lesion (lesions not suitable for VATS wedge re-
sectionwith nodiagnosis underwent openwedge resection before lobectomy).
Operating time was defined as time from first incision to time of closure and
also included times for VATS wedge resection and frozen section examina-
tion. Patients in the robotic group gave written informed consent to undergo
the robotic approach. The patients in the open surgery group also gave written
informed consent for their operations. The study was approved by the Euro-
pean Institute of Oncology’s Ethical Committee.
Surgical Technique
The patient was placed in the lateral decubitus position and single-lung
anesthesia was achieved via a double-lumen endotracheal tube. Patients
were prepared and draped with the arm down, but if conversion to open sur-FIGURE 1. Positions o
20 The Journal of Thoracic and Cardiovascular Surgegery was necessary the arm was moved up and lateral muscle-sparing tho-
racotomy performed. The robot was positioned at the head of the patient,
with the console (the station where the surgeon worked) in the same
room (Figure 1).
Port positions and VATS resection. Three port incisions and
a 3-cm utility thoracotomy were made at the positions indicated in Figure 2.
The ports were standard for all lobectomies except that, on the right side, the
camera port through the seventh intercostal space was in the midaxillary
line, whereas on the left side this port was moved 2 cm posteriorly (com-
pared with the right) to avoid the heart obscuring vision of hilar structures.
The utility thoracotomy was at the fourth intercostal space anteriorly.
Lesions without a preoperative diagnosis were first excised by traditional
VATS wedge resection followed by intraoperative frozen section examina-
tion. Small or deep undiagnosed lesions were located before the operation
(not more than 24 hours before) by injecting technetium 99m–labeled sulfur
colloid under CT control. A gamma ray–detecting probe was introduced
through a port to precisely locate the ‘‘hot’’ nodule and hence guide the
wedge resection.
Hilar dissection. The lobectomy proceeded first by isolation of hilar
elements using a hook and two Cadiere forceps (Intuitive). The hook was
manipulated by the right arm of the robot introduced through the utility tho-
racotomy for right-side dissections or through the posterior trocar in the
eighth intercostal space for left-side lobectomies. One of the Cadiere forceps
(fourth robotic arm) was used to retract the lung and expose structures. The
other Cadiere forceps was manipulated by the left arm of the robot and used
to grip structures during dissection: it was introduced through the utility tho-
racotomy for left-side lobectomies or through the posterior trocar in the
eighth intercostal space for right-side lobectomies. When a hilar vessel or
bronchus was ready to be surrounded with a vessel loop for stapler introduc-
tion, a third Cadiere forceps was introduced (substituting for the hook). Ves-
sels and the bronchus were sectioned by mechanical staplers introduced
through a thoracoscopic port by the assistant surgeon after removal of a ro-
botic arm. The pulmonary vein was usually the first structure to be isolated
and divided. If the lesion was in the right upper lobe, vein resection was fol-
lowed by isolation of the branches of the pulmonary artery and sectioning,
followed by isolation of the bronchus and bronchus sectioning. If the lesion
was in the right lower lobe or left lung, after pulmonary vein sectioning, the
bronchus was usually isolated and stapled before the artery. When middle
lobectomy was being performed, the most favorable sequence was vein,
bronchus, and artery.
Fissure completion and lobe removal. The incomplete fissure
was usually prepared with an Endo Gia stapler introduced by the assistant
surgeon through one of the ports. The lobe was extracted through the ante-
rior utility thoracotomy using an EndoCatch device (Autosuture; Covidien,
Dublin, Ireland).
Mediastinal lymph node dissection. Radical lymph node dis-
section was performed after lobectomy (in open surgery, suspicious lymph
nodes are usually removed before lobectomy), using the same technique as
in open surgery.16,17 Paratracheal lymph node dissection was performed onf robot and surgeon.
ry c July 2010
FIGURE 2. Trocar insertion points for robotic right lung lobectomy.
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the superior vena cava and the azygos vein was incised. The lymph nodes,
together with the fatty soft tissue of the region of Barety, were removed en
bloc with the hook and a Cadiere forceps. Sometimes a PK system (Ultra-
cision, Inc, Santa Clara, Calif) was used in patients with large quantities
of mediastinal fat.
The nodes of the subcarinal station were removed after resection of the
pulmonary ligament and retraction of the lung toward the anterior medias-
tinum to expose the posterior mediastinum. Bronchial arteries could usually
be avoided thanks to the good visibility. If not, they were simply coagulated;
usually a clip was not required. Fibrin sealant (Tissucol, Baxter Healthcare
Corp, Santa Ana, Calif)18 was applied to lymphadenectomy sites to reduce
lymphorrhea, to the bronchial stump, and to the fissure surface to reduce air
leakage. Two 28F (Tyco Healthcare Switzerland, Wollerau, Switzerland)
pleural drains were positioned at the end of the operation.
Statistical Analysis
Because of the nonrandomized nature of the study, we used propensity
score matching to adjust for differences in demographic and clinical charac-
teristics of patients who underwent open and robotic surgery. A multivari-
able logistic regression model was fitted to estimate the relative odds of
undergoing robotic versus open surgery in relation to the following preop-
erative characteristics: age, sex, clinical tumor stage, clinical node status,
body mass index, smoking status, American Society of Anesthesiologists
score, FEV1 percent predicted, and cardiovascular comorbidity, in the
whole study population. The logistic model was used to generate a propen-
sity score for each individual in the data set. The propensity score is the
probability of receiving robotic versus open surgery given the covariates
of the model. Each of the 54 patients who underwent robotic surgery was
then matched to controls (open surgery) on the propensity score using the
GREEDMTCH SAS macro (http://www2.sas.com/proceedings/sugi26/
p214-26.pdf).
We used Fisher’s exact test and the Mantel–Haenszel c2 test for trend to
assess differences in the distribution of characteristics between the 2 treat-
ment groups. Because the small size of the groups and nonnormal distribu-
tions of continuous variables (FEV1, operating time, postoperative
hospitalization, number of lymph nodes removed), the nonparametric Wil-
coxon test was used to assess differences in median values for these vari-
ables. We plotted operating time against date of operation and derived
from it a trend line based on a polynomial regression model. We divided
patients who underwent robotic surgery into three series (tertiles) of 18
patients each. We used the nonparametric Wilcoxon test to assessThe Journal of Thoracic and Cdifferences in operating time and postoperative hospitalization between
the first and second and the second and third robotic series, and also between
the second plus third robotic series and patients who received open lobec-
tomy.
All statistical tests were 2-sided. The statistical analyses were performed
with the SAS statistical software version 8.2 (SAS Institute, Inc, Cary, NC).RESULTS
Table 1 shows the characteristics of the 54 patients with
lung cancer (including converted cases) who underwent ro-
botic lobectomy and the 54 patients who underwent open
surgery and were matched to the robotic group by propensity
score. In the robotic group, we performed 16 right upper lo-
bectomies, 4 middle lobectomies, 11 right lower lobecto-
mies, 14 left upper lobectomies, and 9 left lower
lobectomies. There were 42 adenocarcinomas, 4 squamous
cell carcinomas, 3 carcinoids, 2 small cell carcinomas, and
3 other non–small cell lung cancers. Similar numbers of
wedge resections with frozen section examination before lo-
bectomy were performed in the open and robotic groups: 22
(41%) in the open and 30 (55%) in the robotic group. Pre-
operative localization with radiotracer was used to find the
nodule during surgery in 12 cases (4 in the open group
and 8 in the robotic group).
Table 2 compares variables between tertiles of the robotic
series to delineate learning and also presents open lobectomy
variables to provide indications of safety and oncologic rad-
icality. In 7 (13%) patients, conversion to open surgery was
necessary: for absence of fissure in 5, other anatomic reason
in 1, and oncologic reason in another. Major complications
were confined to the first two tertiles of the robotic group
and consisted of acute respiratory distress syndrome in 2
and transitory neuropathy of the right hand with hypofunc-
tion in another. The latter complication was probably related
to the patient’s position during surgery. Major and minor
complications declined across the three robotic tertiles (P
trend ¼ .04). The numbers of postoperative complications
were similar in the open and robotic groups (P¼ .77); in par-
ticular, similar numbers of patients had postoperative atrial
fibrillation (4 vs 3), air leak (5 vs 2), and pulmonary compli-
cations (4 vs 7) in the open and robotic group, respectively.
No 30-day postoperative mortality occurred. Postoperative
blood transfusion was not required by any robotic surgery
patient but was required by 3 (6%) open surgery patients
(P ¼ .12).
The numbers of lymph nodes removed were similar in the
2 groups (P ¼ .24). However, the median number of medi-
astinal lymph nodes removed was less in the robotic series
(P ¼ .04). Median postoperative hospitalization declined
across the robotic series and was significantly shorter (P ¼
.002) in the third plus second tertile than the first one, and
was significantly shorter for the robotic group (excluding
the first tertile) than the open lobectomy group (4.5 days
vs 6 days; P ¼ .002).ardiovascular Surgery c Volume 140, Number 1 21
TABLE 1. Clinical and pathologic characteristics of patients with 54
lung cancer who underwent robotic lobectomy and 54 matched lung
cancer controls who underwent open lobectomy
Characteristic
Robotic lobectomy
(n ¼ 54)
Open lobectomy
(n ¼ 54) P value
Sex
Men 38 34
Women 16 20 .41
Age (y)
<55 8 11
55–59 12 13
60–64 19 14
65þ 15 16 .54y
FEV1% predicted
Mean (SD) 95 (19) 95 (20) .91z
Median (range) 95 (49–141) 90 (66–169) .48x
Lobe
Lower 20 21
Middle 4 2
Upper 30 31 .70
Clinical tumor stage
cT1 45 48
cT2 9 6 .40
Clinical lymph node status
cN0 51 51
cN1 2 2
cN2* 1 0
cN3* 0 1 .80y
ASA score
1 11 10
2 37 34
3 6 10 .41y
BMI
<18.5 1 1
18.5–25 24 25
25–30 24 21
30 5 7 .91y
Cardiac comorbidity
No 48 46
Yes 6 8 .57
Smoking status
Never smoked 2 2
Ex-smoker 18 17
Current smoker 34 35 .98
Pathologic disease stage
I 45 42
II 5 4
III 4 8 .46
pT1 43 34
pT2 9 16
pT3 0 0
pT4 2 4 .10y
pN0 46 44
pN1 6 5
pN2 2 5 .39y
FEV1, Forced expiratory volume in 1 second; SD, standard deviation; ASA, American
Society of Anesthesiologists; BMI, body mass index. *Mediastinoscopy excluded
lymph node involvement in these 2 patients with cN2 and cN3 yMantel–Haenszel
c2 test for trend zt test xnonparametric Wilcoxon test.
General Thoracic Surgery Veronesi et al
22 The Journal of Thoracic and Cardiovascular Surge
G
T
SFigure 3 shows time trends for the duration of the robotic
and open procedures. Operating time was about an hour lon-
ger for robotic than for open surgery (P< .0001). Median
duration of robotic surgery (including conversions) was 43
minutes shorter in the second and third tertile compared
with the first (P ¼ .02).
DISCUSSION
Modern medicine places greater emphasis than in the past
on the wishes, comfort, and quality of life of the patient. Less
invasive techniques for oncologic surgery that maintain on-
cologic radicality and reduce pain, surgical inflammation,
and postoperative dysfunction3-8, fit squarely within this
philosophy and may bring the added benefit of improved
survival.18,19 Thoracoscopic procedures can attain these
goals in selected patients with lung cancer, but they are un-
comfortable and difficult (long learning curves) for the sur-
geon, with visual information limited to 2 dimensions, and
instruments having restricted maneuverability mainly be-
cause of the rigid axes that are fixed to the thoracic wall
by the entry trocar.15,19
The advanced engineering embodied in the da Vinci Sys-
tem has now made it possible to overcome many of these
disadvantages, without compromising oncologic radicality
or patient safety. Robotic surgery for thoracic disease is
therefore likely to become widespread, provided that the
high costs of the early robotic systems can be significantly
reduced.
Robotic surgery in humans was first described by Cadiere
and associates20 in 1997. Today the commonest indication
for robotic thoracic oncology is resection of mediastinal
masses.21 with relatively few publications on robotic lobec-
tomy for lung cancer.13-15 The experience reported in the
present study suggests that robotic lobectomy for lung can-
cer is feasible and safe. We had no major complications or
bleeding that required urgent conversion to open surgery,
and postoperative complications were similar to those in
our series of patients with open surgery operated on over
the same period for closely similar disease (Table 1). The no-
table difference was that postoperative hospital stay was
shorter in the robotic series than the open series, although
we may have tended to discharge robotically treated patients
sooner than open cases.
We consider that the learning phase for the technique
lasted for the first 18 patients (Table 2) and this appears
shorter than the average of 30 to 35 operations reported
for VATS lobectomies.22
One of the most important differences in the robotic tech-
nique compared with VATS is that it requires the surgeon to
abandon the operating table and sit at a control console, so
that all tactile feedback is lost, and a new set of manual
and eye-hand coordination skills must be acquired.15
Thirteen percent of our cases were converted to open sur-
gery. This is in the middle of the range reported for VATSry c July 2010
TABLE 2. Comparison of learning variables between the three tertiles of robotic surgery patients and the open surgery group
Robotic lobectomy P value*
First tertile,
series 1
Second tertile,
series 2
Third tertile,
series 3
Open
lobectomy
First vs secondþ third
robotic series
Secondþ third
robotic series vs open
No. of operations 18 18 18 54
No. of conversions 3 (17%) 1 (6%) 3 (17%) N/A .67 –
No of complications 6 (33%) 4 (22%) 1 (6%)y 10 (19%) .15 .77
Major/minor 4/2 3/1 1/0 9/1
Blood transfusions 0 0 0 3 – –
Median operating
time, min (range)
260 (152–513) 213 (165–351) 235 (146–304) 154 (74–224) .02 <.001
Median postop
hospitalization, d (range)
6 (4–24) 5 (3–23) 4 (4–7) 6 (3–19) .002 .002
Median No. of lymph
nodes removed (range)
15 (4–37) 17 (4–28) 17 (9–30) 18 (4–27) .24 .72
Median No. of lymph
nodes removed at first
level (range)
9 (3–20) 10 (0–19 12 (3–23) 10 (2–21) .46 .55
Median No. of lymph
nodes removed at second
level (range)
4 (0–18) 6 (1–21) 4 (2–25) 7 (0–17) .34 .04
*Nonparametric Wilcoxon test for continuous variables; Fisher’s exact test for categorical variables (number of conversion, number of complication) ytrend across robotic series
P ¼ .04.
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and Fuller,9 19% by Yim and colleagues,18 and 23% by Ro-
viaro and associates.8 Regarding robotic series, Park, Flores,
and Rusch14 reported a conversion rate of 12%, Gharago-
zloo, Margolis, and Tempesta,15 who described a hybrid ro-
botic-VATS technique carried out on 61 patients, reported
a remarkable 0% conversion rate, while Kernstine, Casan-
dra, and Falabella23 reported a 3% conversion rate in their
experience with three-arm robotic lobectomies.FIGURE 3. Comparison of operating time trends in 54 lung cancer pa-
tients subjected to robotic lobectomy and 54 matched lung cancer patient
controls who underwent open surgery.
The Journal of Thoracic and CRobotic surgery required about an hour more to complete
than open surgery, even at the end of the learning curve. Me-
dian duration of robotic surgery was 217 minutes for the last
two tertiles of our series; this is similar to the 218 minutes
reported by Park, Flores, and Rusch14 in 34 published cases
and the 240minutes reported by Gharagozloo,Margolis, and
Tempesta.15
Our data on number of lymph nodes removed provide
some indication of the likely oncologic radicality of the ro-
botic operation.16,17 Although the number of lymph nodes
removed tended to increase with experience, there was no
significant difference between the robotic and open proce-
dures in terms of lymph nodes removed. Increasing use of
high-resolution CT reduces the risk of leaving occult lung le-
sions in residual lobes—a phenomenon described in relation
to lack of palpation associated with VATS11—thereby sup-
porting the use of minimally invasive surgery.
Over the past 2 years we have standardized to a four-arm
technique not described previously. Use of a fourth arm
brings major advantages compared with the three-arm tech-
nique in use so far13-15: it limits the requirement to change
instruments by the assistant, avoiding possible conflicts be-
tween thoracoscopic and robotic instruments; it permits ma-
neuver/retraction of the lung directly by the surgeon at the
console; it allows exposure and tensioning of the operating
field exactly as the surgeon prefers so that it is more stable;
and it also allows the assistant at the table to use the utility
incision to insert ancillary instruments such as aspirator or
sponge, as required. The availability and at least one robotic
Cadiere forceps into the chest also allows the surgeon to deal
with potentially severe problems like major hemorrhage. Weardiovascular Surgery c Volume 140, Number 1 23
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tients and for all types of lobectomy, while for most VATS
or robotic techniques, the position of the trocars varies ac-
cording to the type of lobectomy.
Other authors have developed different techniques. Ghar-
agozloo, Margolis,and Temp15 perform a VATS lobectomy,
adding the robot to do the lymphadenectomy. Kernstine, Ca-
sandra, and Falabella23 do a completely robotic lobectomy
with three arms, but enlarge the axillary port to a (variable)
size sufficient to extract the lobe and mass. Park, Flores, and
Rusch14 use a three-arm technique but, like us, employ a util-
ity incision to extract the lobe.
We have limited indications for the robotic approach so
far to patients with early-stage lung cancer who are candi-
dates for standard lobectomy with no major respiratory im-
pairment. Indications may expand in the near future to
patients with cardiologic comorbidities, those who have
been pretreated, and those requiring a typical segmentec-
tomy. However, patients with functional impairment seem
at increased risk of postoperative acute respiratory distress
syndrome,24 probably in relation to the long duration of
the operation during which operated lung is excluded from
ventilation. The 2 patients in whom adult respiratory distress
syndrome developed were treated at the beginning of our ex-
perience when selection criteria did not take full account of
functional variables. Although FEV1 percent predicted was
over 65% of predicted in both cases, preoperative arterial
oxygen tension (50%–60%) and arterial oxygen saturation
(91%–92%) were not optimal. The operations lasted 285
and 225 minutes but did not require transfusion or conver-
sion. As a result of experience with these 2 cases, we added
blood-gas analysis to the preoperative work-up.
We expect that the postoperative hospitalization period
can be further reduced by liberal use of sealant and fibrin
glue to limit fluid and air leakage, and hence reduce the
time that drains need to be in place. It may also be possible
to further reduce operating time when a robotic mechanical
stapler, at present not available, is introduced.
With regard to costs, we calculated that each robotic pro-
cedure was associated with an overcost of about 2000 euro
compared with open surgery or VATS, but this would re-
duce if the robotic system were used more extensively (the
break-even point was calculated at 254 procedures per
year all disciplines). Robotic systems will be extensively de-
veloped and improved in the near future, resulting in further
simplification of the technique and encouraging wider ac-
ceptance.
An important limitation of the present study are that it is
observational and that our comparison group of open sur-
gery patients—operated on the same time period in the
same institution—were selected retrospectively. However,
we applied the same inclusion and exclusion criteria to the
both groups to reduce selection bias and residual confound-
ing, and we approached the study as if it were a randomized24 The Journal of Thoracic and Cardiovascular Surgetrial using propensity score matching to create 2 groups well
balanced for all measured baseline characteristics (Table
1).25 Clearly, randomized controlled trials are necessary to
establish the real advantages of the technique.
A second limitation is that comparative data on early and
late postoperative pain and quality of life, postoperative re-
spiratory function, and immune system activation are not
available. It will be important to obtain this information to
further validate the robotic procedure. Finally, comparison
with VATS lobectomy will be important to assess the real
benefits of the robotic approach. This comparison was not
possible at our institute, as our standard approach to lung lo-
bectomy is muscle-sparing thoracotomy.
To conclude, the present study indicates that our method
of robotic lobectomy with lymph node dissection is feasible
and safe for the treatment of early-stage lung cancer and ap-
pears to provide an oncologically adequate resection, justify-
ing further assessment of the robotic system in lung
lobectomy.
We thank Raffaella Bertolotti for general data management, Nic-
ole Rotmentsz for designing the database, and Don Ward for pro-
fessional help with the English.
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